User: Guest  Login
More Searchfields
Simple search
Title:

Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.

Document type:
Article; Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Ormhøj, Maria; Scarfò, Irene; Cabral, Maria L; Bailey, Stefanie R; Lorrey, Selena J; Bouffard, Amanda A; Castano, Ana P; Larson, Rebecca C; Riley, Lauren S; Schmidts, Andrea; Choi, Bryan D; Andersen, Rikke S; Cédile, Oriane; Nyvold, Charlotte G; Christensen, Jacob H; Gjerstorff, Morten F; Ditzel, Henrik J; Weinstock, David M; Barington, Torben; Frigault, Matthew J; Maus, Marcela V
Abstract:
PURPOSE: T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging. EXPERIMENTAL DESIGN: We developed a novel CAR construct directed against CD79b, a critical receptor for successful B-cell development that remains highly expressed in sev...     »
Journal title abbreviation:
Clin Cancer Res
Year:
2019
Journal volume:
25
Journal issue:
23
Pages contribution:
7046-7057
Fulltext / DOI:
doi:10.1158/1078-0432.CCR-19-1337
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/31439577
Print-ISSN:
1078-0432
TUM Institution:
Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie
 BibTeX